| Wang Dongqing,Zhai Limin,Gao Min,et al.Clinical and dosimetric factors for radiation-induced hypothyroidism following intensity-modulated radiotherapy in patients with head-and-neck cancer[J].Chinese Journal of Radiological Medicine and Protection,2014,34(3):201-205 |
| Clinical and dosimetric factors for radiation-induced hypothyroidism following intensity-modulated radiotherapy in patients with head-and-neck cancer |
| Received:June 19, 2013 |
| DOI：10.3760/cma.j.issn.0254-5098.2014.03.011 |
| KeyWords:Head-and-neck cancer Intensity-modulated radiotherapy Hypothyroidism |
| FundProject: |
| Author Name | Affiliation | E-mail | | Wang Dongqing | 5th Department of Radiation Oncology of Shandong Tumor Hospital, Jinan 250117, China | | | Zhai Limin | 5th Department of Radiation Oncology of Shandong Tumor Hospital, Jinan 250117, China | lwwzlm@sina.com | | Gao Min | 5th Department of Radiation Oncology of Shandong Tumor Hospital, Jinan 250117, China | | | Yang Zhengqiang | 5th Department of Radiation Oncology of Shandong Tumor Hospital, Jinan 250117, China | | | Yu Qingxi | 5th Department of Radiation Oncology of Shandong Tumor Hospital, Jinan 250117, China | | | Gong Heyi | 5th Department of Radiation Oncology of Shandong Tumor Hospital, Jinan 250117, China | | | Tang Xiaoyong | 5th Department of Radiation Oncology of Shandong Tumor Hospital, Jinan 250117, China | | | Han Li | 5th Department of Radiation Oncology of Shandong Tumor Hospital, Jinan 250117, China | | | Jiang Lixi | 5th Department of Radiation Oncology of Shandong Tumor Hospital, Jinan 250117, China | |
|
| Hits: 3721 |
| Download times: 3309 |
| Abstract:: |
| Objective To determine the clinical and dosimetric factors associated with radiation-induced hypothyroidism (HT) in head-and-neck cancer patients treated with intensity-modulated radiotherapy (IMRT). Methods The clinical data of 28 head-and-neck cancer patients undergoing IMRT (with the prescribed radiation dose of neck ≥ 40 Gy) plus chemotherapy were retrospectively recruited. The serum levels of thyroid-stimulating hormone (TSH), free triiodo-thyronine (FT3), and free thyroxine (FT4) of each patient were recorded basally and at different times after the end of therapy. Primary HT was defined as increased TSH with or without decreased FT3 and/or FT4. Based on each patient's dose-volume histogram (DVH), the volume percentages of thyroid absorbing 5-50 Gy at interval of 5 Gy were estimated (marked as Vx, x=5-50) together with the mean thyroid dose (MTD), maximum dose (Dmax) and thyroid volume (TV). To evaluate the clinical and dosimetric factors associated with HT, univariate and multivariate logistic regression analysis were performed. Results The median serum levels of TSH, FT3, and FT4 before treatment were 1.51 μU/ml, 5.38 pmol/L, and 18.57 pmol/L, respectively. During the follow-up time of of 15 months (3-57 months), 14 patients (50.0%) developed HT, and the median time for firstly detected HT was 8 months (2-23 months) after treatment. The median serum levels of TSH, FT3, and FT4 when HT was firstly detected were 7.48 μU/ml (4.67-60.11 μU/ml), 4.05 pmol/L (0.40-5.77 pmol/L), and 12.32 pmol/L (4.12-21.25 pmol/L) respectively. There was a significant increasing in TSH level in patients with HT during the follow-up (P<0.05). The TV of the patients with HT was significantly lower than those without HT (Z=-2.154, P<0.05). Univariate analysis showed that younger age and V40 ≥ 80% were associated with a higher risk of HT (χ2=11.340, 4.102; OR=30.0, 9.17; P<0.05). Multivariate analysis confirmed that age and V40 were the independent predictors (OR=34.7, 6.13; P<0.05). Conclusions HT after IMRT for head-and-neck cancer is accompanied by elevated TSH levels. Younger age, smaller thyroid volume, and V40 ≥ 80% have been identified as risk factors for HT after IMRT. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
